Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2011 - 2026)
Catalyst Pharmaceuticals (CPRX) reported Gains from Investment Securities of $12.4 million for Q1 2026, up 1836.79% on a YoY basis from $642000.0 in Q1 2025, and up 1263.4% quarter-over-quarter from $912000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2011 - 2026) Analysis & Trends
Catalyst Pharmaceuticals has reported Gains from Investment Securities for 16 years, with the latest figure at $12.4 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 1836.79% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (down 46.68% YoY), and the FY2025 full-year result was $12.2 million, down 6.91% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $12.4 million, up from $912000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $31.1 million in Q4 2022, with the low at $35693.0 in Q1 2024.
- Historically, Gains from Investment Securities has averaged $6.2 million across 5 years, with a median of $642000.0 in 2025.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities slumped 97.87% — and 2025, when it soared 34015.98%.
- Catalyst Pharmaceuticals' Gains from Investment Securities stood at $31.1 million in 2022, then slumped by 30.15% to $21.7 million in 2023, then tumbled by 97.87% to $464000.0 in 2024, then jumped by 96.55% to $912000.0 in 2025, then soared by 1263.4% to $12.4 million in 2026.
- The last three Gains from Investment Securities figures came in at $12.4 million (Q1 2026), $912000.0 (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Catalyst Pharmaceuticals | 3.84 Bn | 3.08 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.43 Mn |
| Mar 31, 2026 | 12.43 Mn |
| Dec 31, 2025 | 912,000.00 |
| Dec 31, 2025 | 912,000.00 |
| Sep 30, 2025 | 11.33 Mn |
| Sep 30, 2025 | 11.33 Mn |
| Jun 30, 2025 | 12.18 Mn |
| Jun 30, 2025 | 12.18 Mn |
| Mar 31, 2025 | 642,000.00 |
| Mar 31, 2025 | 642,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Sep 30, 2024 | 35,693.00 |
| Sep 30, 2024 | 35,693.00 |
| Jun 30, 2024 | 35,693.00 |
| Jun 30, 2024 | 35,693.00 |
| Mar 31, 2024 | 35,693.00 |
| Mar 31, 2024 | 35,693.00 |
| Dec 31, 2023 | 21.74 Mn |
| Dec 31, 2023 | 21.74 Mn |